Employee Post-Travel Disclosure of Travel Expenses

Date/Time Stamp:
RECEIVED
SECRETARY OF THE SENATE
PUBLIC RECORDS
2019 SEP 19 PM 2:47

Post-Travel Filing Instructions: Complete this form within **30 days** of returning from travel. Submit all forms to the **Office of Public Records in 232 Hart Building.**

In compliance with Rule 35.2(a) and (c), I make the following disclosures with respect to travel expenses that have been or will be reimbursed/paid for me. I also certify that I have attached:

☒ The **original** *Employee Pre-Travel Authorization* (Form RE-1), **AND**
☒ A **copy** of the *Private Sponsor Travel Certification Form* with all attachments (itinerary, invitee list, etc.)

Private Sponsor(s) (list all): PATH/Global Health Technologies Coalition (GHTC) & International AIDS Vaccine Initiative (IAVI)

Travel date(s): August 17 - 24, 2019

Name of accompanying family member (if any): _____
Relationship to Traveler: ☐ Spouse ☐ Child

IF THE COST OF LODGING **DID NOT INCREASE** DUE TO THE ACCOMPANYING SPOUSE OR DEPENDENT CHILD, ONLY INCLUDE LODGING COSTS IN EMPLOYEE EXPENSES. (Attach additional pages if necessary.)

Expenses for Employee:

	Transportation Expenses	Lodging Expenses	Meal Expenses	Other Expenses (Amount & Description)
☐ Good Faith Estimate ☒ Actual Amount	$2,372.17	$942.04	$139.23 (good faith estimate - two catered meal costs estimated)	$51.50 (Ugandan visa application cost)

Expenses for Accompanying Spouse or Dependent Child (if applicable):

	Transportation Expenses	Lodging Expenses	Meal Expenses	Other Expenses (Amount & Description)
☐ Good Faith Estimate ☐ Actual Amount				

Provide a description of all meetings and events attended. *See* Senate Rule 35.2(c)(6). (Attach additional pages if necessary.): See attached itinerary for full description of all meetings and events attended

09/19/19 (Date) Angela Rampoldi (Printed name of traveler) (Signature of traveler)

TO BE COMPLETED BY SUPERVISING MEMBER/OFFICER:

I have made a determination that the expenses set out above in connections with travel described in the *Employee Pre-Travel Authorization* form, are necessary transportation, lodging, and related expenses as defined in Rule 35.

09/19/19 (Date) (Signature of Supervising Senator/Officer)

(Revised 1/3/11) **Form RE-2**

0000000052969

PRIVATE SPONSOR TRAVEL CERTIFICATION FORM

This form must be completed by any private entity offering to provide travel or reimbursement for travel to Senate Members, officers, or employees (Senate Rule 35, clause 2). Each sponsor of a fact-finding trip must sign the completed form. The trip sponsor(s) must provide a copy of the completed form to each invited Senate traveler, who will then forward it to the Ethics Committee with any other required materials. The trip sponsor(s) should **NOT** submit the form directly to the Ethics Committee. Please consult the accompanying instructions for more detailed definitions and other key information.

The Senate Member, officer, or employee **MUST** also provide a copy of this form, along with the appropriate travel authorization and reimbursement form, to the Office of Public Records (OPR), Room 232 of the Hart Building, within thirty (30) days after the travel is completed.

---

1. Sponsor(s) of the trip (please list all sponsors): PATH / Global Health Technologies Coalition (GHTC)* & International AIDS Vaccine Initiative (IAVI) (*see Addendum for explanation of PATH/GHTC)

2. Description of the trip: This trip is an opportunity to see how firsthand how US investments in research and development (R&D) in Uganda are making an impact on key global health challenges.

3. Dates of travel: August 17 - 24, 2019

4. Place of travel: Kampala and Entebbe, Uganda

5. Name and title of Senate invitees: see Addendum

6. I *certify* that the trip fits one of the following categories:

   ☐ (A) The sponsor(s) are not registered lobbyists or agents of a foreign principal **and** do not retain or employ registered lobbyists or agents of a foreign principal **and** no lobbyist or agents of a foreign principal will accompany the Member, officer, or employee *at any point* throughout the trip.

   – OR –

   ☒ (B) The sponsor or sponsors are not registered lobbyists or agents of a foreign principal, but retain or employ one or more registered lobbyists or agents of a foreign principal and the trip meets the requirements of Senate Rule 35.2(a)(2)(A)(i) or (ii) *(see question 9)*.

7. ☒ I *certify* that the trip will not be financed in any part by a registered lobbyist or agent of a foreign principal.

   – AND –

   ☒ I *certify* that the sponsor or sponsors will not accept funds or in-kind contributions earmarked directly or indirectly for the purpose of financing this specific trip from a registered lobbyist or agent of a foreign principal or from a private entity that retains or employs one or more registered lobbyists or agents of a foreign principal.

8. I *certify* that:

   ☒ The trip will not in any part be planned, organized, requested, or arranged by a registered lobbyist or agent of a foreign principal except for *de minimis* lobbyist involvement.

   – AND –

   ☒ The traveler will not be accompanied on the trip by a registered lobbyist or agent of a foreign principal except as provided for by Committee regulations relating to lobbyist accompaniment (*see question 9*).

9. **USE ONLY IF YOU CHECKED QUESTION 6(B)**
I *certify* that if the sponsor or sponsors retain or employ one or more registered lobbyists or agents of a foreign principal, one of the following scenarios applies:

☐ (A) The trip is for attendance or participation in a one-day event (exclusive of travel time and **one** overnight stay) and no registered lobbyists or agents of a foreign principal will accompany the Member, officer, or employee *on any segment* of the trip.

– OR –

☐ (B) The trip is for attendance or participation in a one-day event (exclusive of travel time and **two** overnight stays) and no registered lobbyists or agents of a foreign principal will accompany the Member, officer, or employee *on any segment* of the trip (*see questions 6 and 10).*

– OR –

☒ (C) The trip is being sponsored only by an organization or organizations designated under § 501(c)(3) of the Internal Revenue Code of 1986 and no registered lobbyists or agents of a foreign principal will accompany the Member, officer, or employee *at any point* throughout the trip.

10. **USE ONLY IF YOU CHECKED QUESTION 9(B)**
If the trip includes two overnight stays, please explain why the second night is practically required for Senate invitees to participate in the travel:

(N/A)

11. ☒ An itinerary for the trip is attached to this form. I *certify* that the attached itinerary is a detailed (hour-by-hour), complete, and final itinerary for the trip.

12. Briefly describe the role of each sponsor in organizing and conducting the trip:

PATH/GHTC & IAVI jointly identified Senate invitees, issued invitations, liaised with Ugandan partners to identify and select site visits for the itinerary, and arranged travel and accommodations. IAVI, through their team in Uganda, is leading logistical arrangements in country, splitting costs...(see Addendum)

13. Briefly describe the stated mission of each sponsor and how the purpose of the trip relates to that mission:

PATH/GHTC is a group of over 30 nonprofit organizations, academic institutions, and aligned businesses advancing policies to accelerate the creation of new drugs, vaccines, diagnostics, and other global health tools. IAVI is a nonprofit (501c3) scientific research organization dedicated to...(see Addendum)

14. Briefly describe each sponsor's prior history of sponsoring congressional trips:

PATH/GHTC, with several partners, sponsored a congressional staff learning trip to the CDC campus in Atlanta in August 2018. PATH/GHTC also served as one of several co-sponsors of a trip to South Africa in 2016 to educate staffers about tuberculosis. IAVI has not previously sponsored a congressional trip.

15. Briefly describe the educational activities performed by each sponsor (other than sponsoring congressional trips):

Both PATH/GHTC & IAVI produce reports and briefing materials on the impact of US investment in global health R&D, meet with congressional and agency representatives to discuss US support of global health R&D, and raise awareness of the importance of R&D to eliminating diseases globally.

16. Total Expenses for Each Participant:

	Transportation Expenses	Lodging Expenses	Meal Expenses	Other Expenses
☒ Good Faith estimate ☐ Actual Amounts	$2,800 (see Addendum for more details)	$1,028 (see Addendum for more details)	$385 (see Addendum for more details)	$51.50 (see Addendum for more details)

17. State whether a) the trip involves an event that is arranged or organized *without regard* to congressional participation **or** b) the trip involves an event that is arranged or organized *specifically with regard* to congressional participation:

B) The trip involves an event that is arranged or organized specifically with regard to congressional participation.

18. Reason for selecting the location of the event or trip

Uganda is a key strategic partner for the US on a range of health and development goals and receives more than $430 million in assistance annually, including R&D funding through NIH, CDC, USAID & DoD.

19. Name and location of hotel or other lodging facility:

Protea Hotel by Marriott Kampala, Elgon Terrace, 9421, John Babiha (Acacia) Avenue, Kampala

Protea Hotel by Marriott Entebbe, 36-40 Sebugwawo Drive, Entebbe Road, Entebbe

20. Reason(s) for selecting hotel or other lodging facility:

Both hotels satisfy security requirements and are centrally located to site visits and meeting locations. The Protea Kampala is centrally located to the Ugandan Ministry of Health and site visits, while the Protea Entebbe is situated close to the Uganda Virus Research Institute, often hosting visitors to the site.

21. Describe how the daily expenses for lodging, meals, and other expenses provided to trip participants compares to the maximum per diem rates for official Federal Government travel:

The daily expense for lodging, meals and other expenses are below the maximum per diem for the days in Kampala but slightly over for the days in Entebbe. The daily expenses for lodging, meals, and other expenses are, in total, below the maximum per diem rates for official Federal...(see Addendum)

22. Describe the type and class of transportation being provided. Indicate whether coach, business-class or first class transportation will be provided. If first-class fare is being provided, please explain why first-class travel is necessary:

Round-trip coach air transportation; ground transportation in a locally-arranged van; transportation via IAVI-owned boat to island communities on Lake Victoria (fuel cost to be reimbursed)

23. ☒ I represent that the travel expenses that will be paid for or reimbursed to Senate invitees do not include expenditures for recreational activities, alcohol, or entertainment (other than entertainment provided to all attendees as an integral part of the event, as permissible under Senate Rule 35).

24. List any entertainment that will be provided to, paid for, or reimbursed to Senate invitees and explain why the entertainment is an integral part of the event:

None

25. I hereby *certify* that the information contained herein is true, complete and correct. (For trips involving more than one sponsor, you *must* include a completed signature page for each additional sponsor):

Signature of Travel Sponsor: Emily Conron

Name and Title: Emily Conron, US Policy and Advocacy Officer, Global Health Technologies Coalition

Name of Organization: PATH

Address: 455 Massachusetts Ave. NW, Suite 1000

Telephone Number: 202.540.4403

Fax Number: 202.457.1466

E-mail Address: econron@ghtcoalition.org

ST 00052000000000

PRIVATE SPONSOR TRAVEL CERTIFICATION FORM

SIGNATURE PAGE FOR ADDITIONAL SPONSOR

(to be completed by each additional sponsor)

I hereby *certify* that the information contained on pages 1-4 of the certification form and any accompanying addenda, all submitted in connection with the August 17 - 24, 2019 trip
Dates of Travel (Month Day, Year)
to Uganda is true, complete, and correct.
Place of Travel

Signature of Travel Sponsor: _____

Name and Title: Jennifer Maple, Advocacy Manager

Name of Organization: International AIDS Vaccine Initiative (IAVI)

Address: 125 Broad Street, 9th Floor

Telephone Number: 212-847-1084

Fax Number: 212-847-1113

E-mail Address: jmaple@iavi.org

0000000052 60

Senate Private Sponsor Travel Certification Form – Addendum

Trip: PATH/GHTC-IAVI Congressional Staff Learning Trip – Uganda

August 17-24, 2019

---

1. Sponsor(s) of the trip (please list all sponsors): PATH / Global Health Technologies Coalition (GHTC)* & International AIDS Vaccine Initiative (IAVI)

- *PATH is a nonprofit (501c3) organization. It is a large global health NGO that uses entrepreneurial insight, scientific and public health expertise, and partnerships with U.S. agencies and private sector partners to develop much-needed health products and help countries, primarily in Africa and Asia, tackle their greatest health needs. *GHTC is a coalition group of over 30 organizations with its secretariat housed within PATH, and is not a separate legal entity.* GHTC brings together nonprofit organizations, academic institutions, and aligned businesses to advance policies to accelerate the creation of new drugs, vaccines, diagnostics and other global health tools. PATH staff designated to support GHTC carry out the operational, administrative, and financial systems needs of GHTC. PATH also provides and maintains overall GHTC focus, direction, and cohesion through priority setting, operational decision-making, and advancing collaboration as well as action among members and partners. PATH leads all decision-making on GHTC's priorities, policy input, and public statements to advance GHTC's objectives.
    - *Throughout the Ethics paperwork for this trip, the organization will be denoted as "PATH/GHTC."*

12. Briefly describe the role of each sponsor in organizing and conducting the trip:

- ...equally with PATH/GHTC. PATH employee Emily Conron, who serves as GHTC's US Policy and Advocacy Officer, and IAVI's Advocacy Manager, Jennifer Maple, will accompany Senate staff on the trip.

13. Briefly describe the stated mission of each sponsor and how the purpose of the trip relates to that mission:

- ...addressing urgent, unmet global health challenges including HIV and tuberculosis. IAVI's mission is to translate scientific discoveries into affordable, accessible public health solutions. Through scientific and clinical research in Africa, India, Europe, and the US, IAVI is pioneering the development of biomedical innovations designed for broad global access, developing vaccines and antibodies in and for the developing world and seeking to accelerate their introduction in low-income countries. This trip advances the missions of both PATH/GHTC and IAVI to build support for public funding of R&D for global health challenges by showcasing how US government R&D investments in Uganda are advancing new health products.

5. Name and titles of Senate invitees:

*Final participant list in **bold***

Adam Yezerski, Professional Staff Member, Subcommittee on State, Foreign Operations, and Related Programs, Committee on Appropriations

Kali Farahmand, Professional Staff Member, Subcommittee on State, Foreign Operations, and Related Programs, Committee on Appropriations

Jeff Reczek, Professional Staff Member, Subcommittee on Labor, Health and Human Services, Education, and Related Agencies, Committee on Appropriations

Sarah Arkin, Democratic Policy Director, Committee on Foreign Relations

Sophia Lalani, Legislative Assistant, Sen. Booker

Kimberly Miller-Tolbert, Legislative Assistant, Sen. Booker

Angela Wiles, Health Policy Director, Sen. Burr

Dan Burgess, Legislative Director, Sen. Blunt

Baxter Carr, Legislative Assistant, Sen. Capito

Dana Richter, Legislative Assistant, Sen. Capito

Lauren Jee, Health Policy Counsel, Sen. Cardin

Kelsey Magill, Legislative Correspondent, Sen. Coons

Jessica McNiece, Health Policy Director, Sen. Durbin

Brooke Jamison, Legislative Director, Sen. Gillibrand

Meghan Dorn, Legislative Aide, Sen. Graham

Scott Graber, Legislative Assistant, Sen. Graham

Elizabeth Henry, Legislative Assistant, Sen. Hyde-Smith

William Dent, Legislative Assistant, Sen. Isakson

Kate Hunter, Legislative Assistant, Sen. Isakson

Kyle Christian, Legislative Assistant, Sen. Moran

Jacob Vance, Legislative Correspondent, Sen. Moran

Anna Dietderich, Legislative Aide, Sen. Murkowski

Angela Ramponi, Legislative Aide, Sen. Murkowski

Matt Squeri, Foreign Policy Advisor, Sen. Merkley

Jessica Elledge, Legislative Assistant, Sen. Murphy

Muad Hrezi, Legislative Correspondent, Sen. Murphy

Robert Nelson, Legislative Correspondent, Sen. Murphy

Ryan Pettit, Senior Advisor, Sen. Murray

Seth Gold, Legislative Assistant, Sen. Portman

Bethany Poulos, Legislative Aide, Sen. Rubio

Liz Banicki, Legislative Assistant, Sen. Sullivan

Jaymi Light, Health Policy Director, Sen. Young

000005257

11. *Complete and final itinerary – separate document*

21. Describe how the daily expenses for lodging, meals, and other expenses provided to trip participants compares to the maximum per diem rates for official Federal Government travel:

- ...Government travel in Kampala and Entebbe combined.

Detailed breakdown of costs (good faith estimates) compared to per diem rates:

Transportation Expenses	Lodging Expenses	Meal Expenses	Other Expenses
$2,800 Flight (coach, roundtrip): $2,500 Van: $250 Boat (fuel reimbursement to partner): $50	**$1,028** (5 nights hotel)	**$385**	**$51.50** Visa fee: $51.50

Day	City	State Department Maximum Per Diem Rate (hotels)	State Department Maximum Per Diem Rate (M&E)	Hotel (incl. breakfast)	Meals
1	Kampala	$250	$90	$214	$77
2	Kampala	$250	$90	$214	$77
3	Entebbe	$172	$73	$200*	$77*
4	Entebbe	$172	$73	$200*	$77*
5	Entebbe	$172	$73	$200*	$77*
	Total:	$1,016	$399	$1,028	$385
		TOTAL: $1,415		**TOTAL: $1,413**	

*Note: The hotel in Entebbe is $28 over the maximum per diem rate and the Entebbe M&E is above the maximum per diem rate by $4 but the total expenses of the entire trip fall below the maximum per diem rates for official Federal Government travel in Kampala and Entebbe combined. The reason for the increased costs in Entebbe for both lodging and M&E is to ensure security requirements are met for the participants during their time outside of the capital city. This includes staying at a hotel with the necessary level of security and providing the majority of meals at the hotel to minimize the movement of participants in Entebbe at night.

0000052608

GHTC global health technologies coalition

IAVI International AIDS Vaccine Initiative

GHTC-IAVI Uganda Congressional Staff Learning Trip

August 17 – 24, 2019

Transit Day – Saturday, August 17

5:35 pm	Depart Washington, D.C. from Dulles to Entebbe (via Brussels) on United Airlines

Transit Day – Sunday, August 18

10:15 pm	Arrival in Entebbe
11:00 pm	Transit to hotel in Kampala and check in

Overnight: Protea Hotel by Marriott Kampala

Day 1 – Monday, August 19
Location: Kampala
Attire: Business

8:30–9:00 am	Breakfast and daily briefing reviewing daily itinerary and introducing points for discussion during site visits *Location*: Protea Hotel by Marriott Kampala
9:00–10:00 am	Welcome and orientation from GHTC and IAVI staff *Location*: Protea Hotel by Marriott Kampala
10:00–10:30 am	Transit to US Embassy and proceed through security
10:30–11:00 am	Courtesy call and introduction to US Mission to Kampala from US Ambassador to Uganda, **Deborah Malac**. Brief presentation to convey how Uganda is a key strategic partner for the US and how US foreign assistance promotes good governance, human rights, and multi-party democracy and addresses key health threats, including HIV/AIDS, emerging infectious diseases, and malaria, including through R&D efforts. *Location*: US Embassy, Kampala
11:00 am–12:00 pm	Meeting with US Mission country team, including **Amb. Malac**; **Colette Marcellin**, Deputy Chief of Mission; **Dr. Lisa Nelson**, Centers for Disease Control and Prevention (CDC) Mission Director; and invited representatives from the President's Emergency Plan for AIDS Relief (PEPFAR), United States Agency for International Development (USAID), National Institutes of Health (NIH), Walter

0000052609

	Reed Army Institute of Research (WRAIR), and the Peace Corps. High-level discussion on US government (USG) investments, strategies, and priorities in Uganda.
12:00–1:00 pm	Lunch – brown bag pre-ordered from Embassy on-site restaurant *Location*: US Embassy, Kampala
1:00–1:30 pm	Briefing on USG-supported research and development (R&D) in Uganda from Interagency Health Team, with representatives from CDC, PEPFAR, USAID, NIH, and WRAIR giving an overview of each agency's unique contribution to global health R&D. Discussion will focus on US government investments, strategies, and priorities in Uganda with regard to R&D, with the goal of giving trip participants an improved understanding of the USG role in partnership with Ugandan researchers. This discussion will help set the stage for site visits and give context to the work that will be seen over the course of the trip. *Location*: US Embassy, Kampala
1:30–2:15 pm	Transit to Public Health Emergency Operations Center adjacent to Ugandan Ministry of Health
2:15–3:15 pm	Tour Public Health Emergency Operations Center (EOC) accompanied by leadership staff and CDC Center for Global Health staff seconded to site. Showcase how the establishment of the EOC, as one of the three major pillars of the CDC Global Health Security Demonstration Project in Uganda, has strengthened political and technical linkages between CDC Uganda and the Ugandan Ministry of Health, and has been leveraged to respond to more than 70 outbreaks and public health events. Highlight how USG investments in products for Ebola preparedness and response are being deployed to strengthen global health security and prevent the further spread of the Ebola epidemic in neighboring Democratic Republic of the Congo, and how these investments are part of USG's commitment to the Global Health Security Agenda. *Location*: Public Health Emergency Operations Center
3:15–3:45 pm	Transit to Ugandan Ministry of Health and proceed through security
3:45–4:45 pm	Courtesy call with Ugandan Ministry of Health (MoH) officials, including Permanent Secretary of the Ministry of Health, **Dr. Diana Atwiine**. Briefing on major health issues facing Uganda and how US-Uganda partnerships on health programs and R&D efforts are making progress. Discussion will touch on both the challenges and opportunities to improve health outcomes in Uganda and the region through R&D. Meeting will help grow participants' understanding of

0000000052 0

	the role of the MoH and how it works in collaboration with USG on shared priorities. *Location*: Ugandan Ministry of Health
4:45–6:00 pm	Transit to evening reception
6:00–7:30 pm	Evening reception with US Chief of Mission. Discussion of the US partnership with Uganda and areas of focus for future collaboration, with an emphasis on opportunities in R&D. *Location*: US Chief of Mission residence
7:30 pm	Transit to hotel, optional dinner onsite

Overnight: Protea Hotel by Marriott Kampala

Day 2 – Tuesday, August 20
Location: Kampala
Attire: Business casual

8:00–8:30 am	Check out of hotel and store bags for evening pick-up
8:30–9:30 am	Breakfast and daily briefing reviewing daily itinerary and introducing points for discussion during site visits *Location*: Protea Hotel by Marriott Kampala
9:30–10:15 am	Transit to Makerere University–Johns Hopkins University Research Collaboration site at Mulago Hospital complex
10:15–11:30 am	Tour of Makerere University–Johns Hopkins University Research Collaboration (MUJHU) site at Mulago Hospital complex. **Dr. Phillipa Musoke**, Site Leader and Principal Investigator for Makerere University, and **Dr. Monica Nolan**, Deputy Director and Site Representative for Johns Hopkins University, will give a short presentation on MUJHU's ground-breaking research on HIV prevention methods for women and the prevention of mother-to-child HIV transmission, emphasizing how USG R&D funding is contributing to the achievement of the elimination of mother to child HIV transmission and promising new research to break the cycle of HIV transmission. The presentation will highlight pivotal studies conducted at the site which have contributed to the development of new tools to prevent HIV/AIDS and informed global guidelines and policies. Over 10,000 women have been enrolled in perinatal HIV prevention trials at MUJHU, including the landmark HIVNET 012 (single dose Nevirapine for mother and baby), HPTN 046 (extended infant NVP prophylaxis during breastfeeding), and

IMPAACT PROMISE (triple antiretroviral therapy during pregnancy and breastfeeding) studies. Results from these studies, supported by NIH and CDC, have directly informed World Health Organization (WHO) policy advances to the current policy recommending antiretroviral therapy for life for all HIV-infected pregnant and breastfeeding women. Other groundbreaking studies conducted at the site have informed improved care of infants, children and women living with HIV and breakthroughs for women to protect themselves from acquiring HIV.

Following this introduction, a facilitated roundtable discussion—featuring MUJHU researchers, a community educator, members of the MUJHU Community Advisory Board, and former study participants—will provide an interactive overview of the impact of community participation in research. Participants will include:
Dr. Clemensia Nakabiito, Research Leader, Women's Health/MTN Site & Investigator, HPTN-084 Study
Dr. Brenda Gati, Investigator, MTN-025 HOPE Study
Dr. Carolyn Akello, Investigator, MTN-034 REACH Study
Dr. Linda Barlow-Mosha, Research Leader, Pediatric and Adolescent Health
Dr. Maxensia Owor, Research Leader, Perinatal and Infant Health and Nutrition
Dr. Agnes Mugagga, Director, Research Quality Division
Ms. Juliane Etima, Director, Pyschosocial Support Division and Behavioral Scientist
Dr. Carol Onyango, Clinical Research Site Coordinator for NIH network studies
Ms. Teopista Nakyanzi, Community Advisory Committee Liaison Officer and Community Team leader
Vincent Sserunjogi, Chair, MUJHU Community Advisory Board
Location: Mualgo Hospital complex

11:30–12:00 pm — Tour of newly refurbished Women's Health HIV Prevention Studies Clinic and youth research clinic. Overview of MUJHU's participation as a clinical research site with the NIH Microbicides Trials Network, including the ASPIRE and HOPE studies of the Dapivirine vaginal ring to reduce HIV infection, and further studies underway, including REACH, to assess safety, adherence and acceptability of the ring in young, pregnant, and breastfeeding women to ensure data on the tool is available on women throughout their age and reproductive life span.
Location: Mualgo Hospital complex

12:00–12:15 pm — Walk to Uganda–Case Western Reserve University Research Collaboration TB Project Clinic (on Mualgo Hospital complex)

0000005272

12:15–1:00 pm

Working lunch with introduction to Uganda–Case Western Reserve University Research Collaboration (UCRC) TB Project Clinic led by **Prof. Harriet Mayanja-Kizza**, site Principle Investigator. The presentation will detail how the UCRC—a highly successful research collaboration between Case Western Reserve University in Cleveland, Ohio; Makerere University in Kampala, Uganda; and the Ugandan Ministry of Health—was formed in 1988 through an NIH grant, and that NIH funding via the Fogarty International Center has provided support for training of over 100 Ugandan physicians and scientists at the site. Prof. Mayanja-Kizza will explain how UCRC has worked with government and other academic and service partners to advance TB care worldwide, and built laboratories and trained clinicians, scientists and epidemiologists over the past 30 years using a collaborative model.
Location: Mualgo Hospital complex

1:00–1:45 pm

Walking tour of the UCRC's TB Project Clinic and facilities led by Prof. Mayanja-Kizza. The tour will showcase the operations of a successful multi-study research clinic, familiarizing participants with general procedures and processes used in the waiting, reception and counselling areas; chart preparation and filing areas; nursing and medical areas; pharmacy store and dispensary; and X-ray and other support areas. Site investigators and leadership staff will briefly describe how these areas function to care for patients and collect data and samples for diagnostic, immunologic and epidemiologic studies, and clinical trials of new drugs and drug combinations for TB prevention and treatment. Representatives from the TB Community Research Advisory Group will describe their work. Participants will have the opportunity to interact with site representatives and will be briefed about several key current studies underway at the site.
Location: Mualgo Hospital complex

1:45–2:30 pm

Following the clinic tour, a presentation—highlighting UCRC's TB and TB-HIV Research collaborations led by **Prof. Harriet Mayanja-Kizza**, Site Principal Investigator; Scientific, Public Health and Laboratory Training for TB Research led by **Prof. Moses Joloba**; and CDC-funded TB Trials Consortium studies conducted on site, including a brief overview of Study 31, by **Dr. Grace Muzanyi**, Site Senior Clinical Coordinator—will give participants a holistic overview of UCRC's research impact. With USG funding from NIH and CDC, and additional support from the European and Developing Countries' Clinical Trials Partnership, Gates Foundation, WHO, and TB Alliance, the UCRC TB Project Clinic at Mulago Hospital has conducted numerous studies—including more than 25,000 participants in total—of the immunology, transmission, diagnosis, prevention and treatment of TB and TB+HIV over the past 30 years, including phase 1, 2 and 3 clinical trials of new drugs, drug combinations and immunotherapeutic agents for the treatment of active and latent TB, TB

	vaccines and TB and antiretroviral therapy; studies of the immunology of TB infection and progression from TB infection to active TB; TB and HIV interactions; TB diagnostics; and the evaluation of new microbial and immunologic biomarkers of response to TB treatment to expedite testing of new TB drugs, drug combinations and vaccines. *Location*: Mualgo Hospital complex
2:30–3:15 pm	Transit to Makerere University Main Campus
3:15–3:25 pm	Briefing by **Dr. Andrew Kambugu**, the Sande-McKinnell Executive Director of the Infectious Diseases Institute (IDI), College of Health Sciences, Makerere University. Dr. Kambugu will give a high-level overview of IDI research supported by NIH, CDC, and international partners that is advancing new products and approaches to combat HIV/AIDS, TB, meningitis, cervical cancer, and other infectious diseases. *Location*: Makerere University Main Campus
3:25–3:40 pm	Overview of NIH Intramural Program in Uganda by **Victor Ssempijja**, Biostatistician with the Clinical Monitoring Research Program Directorate.
3:40–4:30 pm	Short overviews of project-specific research highlights, including poster presentations on key global health research findings supported by IDI, led by **Dr. Barbara Castelnuovo**, Head of Research, IDI.
4:30–5:00 pm	Tour of the Bioinformatics and Big Data Centre, led by **Dr. Daudi Jjingo**, Program Director/Principal Investigator for the Ugandan NIH H3Africa bioinformatics training program. Makerere University, in partnership with the NIH National Institute of Allergy and Infectious Diseases and the Office of Cyber Infrastructure and Computational Biology, launched the African Centre of Excellence (ACE) in Bioinformatics and Data Intensive Sciences in March. The first facility of its kind in the region, the ACE serves as a center for computational biology and big data analysis and supports graduate and post-graduate training in bioinformatics, R&D support, human and pathogen DNA sequencing, biostatistics and image processing, and virtual reality (VR) infrastructure and services. The tour will highlight the state-of-the-art VR, tele-learning, and high-performance computing facilities. *Location*: IDI McKinnell Centre, Makerere University Main Campus
5:00–5:45 pm	Transit to dinner

5:45–7:00 pm	Dinner with early-career investigators based at IDI and Dr. Kambugu to learn more about their specific research areas and the impact of USG support for research and training in infectious diseases. *Location*: Cantine Divino Restaurant
7:00–7:30 pm	Transit to hotel; pick up bags *Location*: Protea Hotel by Marriott Kampala
7:30–8:30 pm	Transit to Entebbe
8:30 pm	Check in to Entebbe hotel

Overnight: Protea Hotel Entebbe

Day 3 – Wednesday, August 21
Location: Entebbe
Attire: Business casual

7:30–8:30 am	Breakfast and daily briefing reviewing daily itinerary and introducing points for discussion during site visits
8:30–9:00 am	Transit to Uganda Virus Research Institute (UVRI) campus
9:00–10:00 am	Meet with **Professor Pontiano Kaleebu**, Director of UVRI, and senior UVRI staff. Participants will gain a holistic understanding of UVRI's research impact, hear about UVRI's mission/mandate and structure, appreciate the facility's long history and contributions to combatting infectious diseases, and learn about the Institute's programmatic activities and research capacities. The Uganda Virus Research Institute (UVRI) is a research institution under the Uganda National Health Research Organization. The Institute was founded in 1936 by the Rockefeller Foundation as a Yellow Fever Research Institute. Presently, UVRI is owned and operated by the Government of the Republic of Uganda with a mandate to carry out research on communicable diseases affecting humanity, with continued emphasis on viral infections. The institution houses specialized laboratories for Arboviruses and Filoviruses in Sub-Saharan Africa, and is best known for the discovery of Zika virus, West Nile virus, Chikungunya virus, Bwamba virus, Semliki forest virus, O'nyong'nyong and Kadam viruses. UVRI was also an early pioneer in HIV/AIDS research and continues groundbreaking work in that field.

0000052275

The UVRI campus in Entebbe hosts several long-term partner organizations, including the CDC, the United Kingdom Medical Research Council, and other non-governmental partners. The facility is home to international, national and regional reference laboratories such as the reference laboratory for HIV (HRL lab), the zoonotic laboratory and a highly specialized biosafety level three (BSL-3) laboratory for Viral Hemorrhagic Fevers (VHF), the high consequence pathogens Medical Research Council Unit, and the EPI/vaccine preventable diseases laboratory which serves as the national center for research and epidemiological investigations of vaccine preventable disease in Uganda and the horn of Africa. The US government, through CDC, DoD, and NIH, has played a critical role in the establishment of many of these laboratories as well as the biosecurity systems in use. The quality of the laboratories and capacity of UVRI are such that the institute also serves as an international reference laboratory, receiving and processing samples from neighboring countries in the region.

10:00 am–12:00 pm

Tour of UVRI campus led by Professor Pontiano Kaleebu, including the following laboratories:

- Arbovirology laboratories
- Viral hemorrhagic fever laboratories
- Expanded Program on Immunization laboratories
- HIV Reference laboratories
- Uganda Medical Informatics Centre
- Medical Research Council (MRC)/UVRI & London School of Hygiene and Tropical Medicine (LSHTM) virology and immunology laboratories

12:00–1:00 pm

Lunch hosted by UVRI

1:00–2:30 pm

Meetings with UVRI-IAVI program staff:
1:00–1:10: General overview of UVRI-IAVI program; **Brenda Okech**, Director
Introductions and presentations from department heads:
1:10–1:30: Clinical programs overview; **Annet Nanvubya**, Clinical Trials Manager
1:30–1:40: Research Pharmacy overview; **Umar Nkuutu**, Pharmacist
1:40–1:50: Site Laboratory overview; **Enoch Muyanja**, Laboratory Manager
1:50–2:00: Data Management overview; **Teddy Nakawesa**, Data Manager
2:00–2:20: Community programs overview; **Gertrude Nanyonjo**, Acting Head of Community Studies
1:50–2:00: Quality Management overview; **David Mugisha**, Quality Coordinator

2:30–3:00 pm

Presentation on HIV Prevention Trial Network (HPTN) 084 LIFE trial (Long-acting Injectable For the Epidemic), a Phase 3 Double Blind Safety and Efficacy Study, by **Juliet Mpendo**, Medical Director & Principal Investigator. Participants will learn about the study design, protocol, ongoing follow-up and potential impact

	of this important Phase III clinical trial. HPTN 084 is a study being done to evaluate the safety and efficacy of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis (PrEP) in HIV-Uninfected Women. PrEP agents are needed that do not depend on daily or near-daily pill-taking. The study is the first large-scale clinical trial of a long-acting injectable medication for HIV prevention in sexually active women. If found to be safe and effective for HIV pre-exposure prophylaxis (PrEP), injectable CAB may be an easier, more desirable, discreet alternative to daily oral TDF/FTC for some women. The development of alternative agents for PrEP, and/or more adherence-friendly schedules for currently available agents, could increase prevention choices and increase acceptability. Long-acting injectable agents have the potential to prevent HIV acquisition without relying on adherence to a daily oral regimen.
3:00–3:10 pm	Tea break; time for group discussion
3:10–4:10 pm	In-depth discussion of community activities and meeting with Community Advisory Board (CAB) members to discuss the impacts of this research, challenges, and presentation of how CAB members ensure buy-in of community leaders and members and prevent myths and mitigate concerns about research within the community. Open Q&A with CAB
4:10–4:40 pm	Discussion with Community Liaison Officers (CLOs). Briefing on structural barriers to accessing healthcare in the Lake Victoria fishing community and overview of what the group will see Thursday. Open dialogue with CLOs about their community outreach work, including challenges, how they became involved, and future directions of biomedical research in the region.
4:40–5:10 pm.	Tour of UVRI Clinic and discussions with **Dr. Mpendo** and team conducting HPTN 084 study. Participants will gain an understanding of what a typical clinic visit is entails for trial participants, learn about the process of enrolling participants (informed consent forms, screenings), see where biomedical samples are collected and the process of analyzing them to determine the trial outcomes.
5:10–5:30pm	Transit to dinner
5:30–7:00 pm	Working dinner – debrief of the day and review of next day's itinerary *Location*: Goretti's Pizzeria

Overnight: Protea Hotel Entebbe

Day 4 – Thursday, August 22
Location: Lake Victoria fishing islands
Attire: Casual (dress to be in direct sun much of the day)

7:30–8:30 am	Breakfast and daily briefing reviewing daily itinerary and introducing points for discussion during site visits *Location*: Protea Hotel Entebbe
8:30–9:00 am	Transit to boat launch site
9:00–10:30 am	Boat transfer to Kimi Island Led by **Gertrude Nanyonjo** and **Mathias Wambuzi**
10:30 am–12:00 pm	Overview of clinical programs on Kimi Island and Q&A with local CAB. Participants will gain an understanding of the research efforts Uganda fishing communities are participating in, structural barriers fisherfolk face in accessing healthcare, and their increased occupational and environment risk for acquiring HIV. A recent study of fisherfolk in Uganda found that 22% were HIV positive, rates being higher among women than men. Risk factors associated with the elevated vulnerability of fisherfolk to HIV infection include being mostly youth or young adults, being mobile, being involved in risky forms of work, being relatively poor and marginalized, being inclined towards alcohol use, and being less able to readily access health services.
12:00–12:30 pm	Boat transfer to Nsadzi Island
12:30–1:30 pm	Lunch (provided by community)
1:30–4:00 pm	Tour of island clinic and ongoing work. Participants will visit another fishing community and see the local clinic that serves these regional islands. They will hear more about the current ongoing research as well as the integrated HIV treatment and care at the health clinic. This site will highlight the important link between research efforts toward new HIV prevention tools and implementation of current tools (though programs like PEPFAR) and how their collaboration increases access to HIV services for a population that would otherwise have limited access to healthcare.
4:00–5:15 pm	Transit to landing site
5:15–5:45 pm	Transit to hotel, time to change

5:45–6:15 pm	Transit to dinner
6:15–7:45 pm	Working dinner – debrief of the day and review of next day's itinerary *Location*: Protea Hotel Entebbe

Overnight: Protea Hotel Entebbe

Day 5 – Friday, August 23
Location: Entebbe
Attire: Casual

8:00–9:00 am	Breakfast and daily briefing reviewing daily itinerary and introducing points for discussion during site visits
9:00–9:30 am	Transit to Zika Forest UVRI research facility
9:30–10:30 am	Tour Zika Forest UVRI research facility tour; overview of UVRI activities. Zika Forest has served as a protected field research station of UVRI since UVRI was established in Entebbe, Uganda in 1936. The 25-acre forest has rich bio-diversity and is home to over 40 types of mosquitoes. It serves as a critical venue for innovative scientific research, offering a platform for surveillance and field studies of emerging and re-emerging infectious diseases. Investigations of mosquitos at Zika Forest started in 1946 as part of the study of human yellow fever. In 1947 researchers at UVRI isolated the RNA of a flavivirus, which was named the Zika Virus. Today, Zika and related Arboviruses such as Yellow Fever, Dengue, West Nile and Japanese Encephalitis pose critical health security threats around the world and have spread outside their geographic areas from Micronesia to the United States. At Zika Forest, the delegation will hear from UVRI leadership on the history of Zika Forest and its impact on global health, citing various research and surveillance activities, key discoveries made, and on-going projects related to Arboviruses such as Yellow Fever, Dengue, West Nile and Zika virus. The delegation will see the observation and baiting tower and will hear about past Yellow Fever research using trapped monkeys. These efforts led to the elucidation of the Yellow Fever virus cycle, along with other research on the ecology of mosquito vectors for arboviruses. The visit will help to emphasize key findings and the global relevance of this research, connections between research conducted at Zika Forest and UVRI, and the impact of the work supported by the US President's Malaria Initiative (PMI) in Uganda. *Location*: Zika Forest UVRI research facility

0000052725

GHTC global health technologies coalition

avi International AIDS Vaccine Initiative

10:30–11:00 am	Transit to Kasenyi landing site clinic
11:00–12:00 pm	Tour the Kasenyi landing site clinic, an HPTN 084 satellite clinic on the shores of Lake Victoria. Participants will tour the facility on an active clinic day to learn about how clinic trial participants are enrolled in the study and witness the operations of a small, local health facility.
12:00–12:30 pm	Tour of landing site led by local political leader (the equivalent of a city council member). He will walk us through the community and highlight aspects of the fishing industry which contribute to an increased risk of acquiring HIV. Participants will gain an understanding of how lifestyles differ slightly from the island based fishing communities and how access to healthcare and general health outcomes differ.
12:30–1:00pm	Transit to UVRI
1:00–2:30 pm	Moderated lunch discussion with early-career investigators at UVRI and Professor Pontiano Kaleebu, Director of UVRI. Discussion of research context in Uganda and motivations to pursue careers in global health research.
2:30–5:00 pm	Break / time to pack
5:00–7:00 pm	Final working dinner and debrief conversation covering impressions from the trip and site visits, as well as time to ask questions and give feedback. *Location*: hotel restaurant
7:00–8:00 pm	Break / check out of hotel
8:00 pm	Transit to Entebbe airport
11:20 pm	Depart for Dulles on United Airlines (via Brussels)

Transit Day – Saturday, August 24

2:20 pm	Arrive at Dulles

GHTC global health technologies coalition

iavi International AIDS Vaccine Initiative

July 2, 2019

Dear Angela:

PATH/Global Health Technologies Coalition (GHTC) and International AIDS Vaccine Initiative (IAVI) are pleased to invite you on a unique learning trip to Uganda, where you will have the opportunity to see firsthand how US investments are working to address key global health challenges through transformative investments in research and development (R&D). The trip will take place from August 17–24, 2019 (including travel days) and will include meetings with US, Ugandan, and NGO partners; visits to research, clinical, and program sites in the field; and interactions with health workers and community members. We hope this trip will be a resource for your office as you consider the US government's role in improving global health, in particular through investments in R&D for new tools like drugs, vaccines, and diagnostics for use in low-resource settings.

Uganda is a hub for cutting-edge scientific research and is a critical partner of the United States on shared global health research objectives. Long-standing partnerships between universities in the United States and Uganda have produced life-saving global health tools and trained a new generation of researchers and clinicians, building the capacity of Uganda and other countries in the region to discover solutions to their most pressing health challenges. Clinical research sites in Uganda have hosted trials that have resulted in new drugs, vaccines, and diagnostics for disease threats that affect populations in both countries, such as HIV/AIDS, and informed global treatment and prevention guidelines. Continued scientific partnership, nourished by US investments through the National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), US Agency for International Development (USAID), Department of Defense, and other agencies, is critical to advance progress against long-standing health threats and prepare for the unknown pathogens of the future.

We will start our trip in the capital city of Kampala, home to some of the preeminent universities and research institutes in Africa. Meetings with key US and Ugandan officials will set the stage for visits to sites including the Makerere University–Johns Hopkins University Research Collaboration at Mulago Hospital focused on HIV prevention, the Uganda–Case Western Reserve University Research Collaboration Tuberculosis Project Clinic, and the Infectious Diseases Institute at Makerere University, where research supported by NIH, CDC, and international partners is advancing new products and approaches to combat HIV/AIDS, TB, meningitis, cervical cancer, and other infectious diseases.

After transiting to nearby Entebbe, we will tour the Uganda Virus Research Institute (UVRI), a international scientific hub known for the discovery of viruses including Zika, West Nile, and Chikungunya, pioneering research in HIV/AIDS, and its capacity as an international reference laboratory. Site visits to see neighboring communities, including some on remote islands on Lake Victoria, will showcase how clinical trials supported by the US government enroll participants to test new health products and interventions, improving health locally and driving global health progress. A tour of the UVRI protected field research station in the Zika Forest—known for the discovery of the virus of the same name—will showcase how research on site has contributed to the understanding of and response to mosquito-borne viruses around the globe. Throughout the week, trip participants will also gain a better understanding of Uganda's leadership in global health security, and how US investments have contributed to the country's preparedness for the potential spread of Ebola from the neighboring Democratic Republic of the Congo.

We hope to have the opportunity to spend a transformative week with you in Uganda seeing the life-saving impact of US global health R&D activities.

Sincerely,

Emily Conron
US Policy and Advocacy Officer
Global Health Technologies Coalition

Jenni Maple
Advocacy Manager
International AIDS Vaccine Initiative

The Global Health Technologies Coalition (GHTC) Secretariat, housed at PATH, is a group of more over 30 nonprofit organizations, academic institutions, and aligned businesses advancing policies to accelerate the creation of new drugs, vaccines, diagnostics, and other tools that bring healthy lives within reach for all people.

The International AIDS Vaccine Initiative (IAVI) is a nonprofit scientific research organization dedicated to addressing urgent, unmet global health challenges including HIV and tuberculosis. Our mission is to translate scientific discoveries into affordable, accessible public health solutions for the people who need them most.

Date/Time Stamp:

ETHIC JUL12'19PM 5:23

EMPLOYEE PRE-TRAVEL AUTHORIZATION

Pre-Travel Filing Instructions: Complete and submit this form at least 30 days prior to the travel departure date to the **Select Committee on Ethics** in **SH-220**. Incomplete and late travel submissions will **not** be considered or approved. This form **must** be typed and is available as a fillable PDF on the Committee's website at ethics.senate.gov. Retain a copy of your entire pre-travel submission for your required post-travel disclosure.

Name of Traveler: Angela Ramponi

Employing Office/Committee: Sen. Murkowski

Private Sponsor(s) (list all): PATH/Global Health Technologies Coalition, International AIDS Vaccine Initiative

Travel date(s): August 17-24, 2019

*Note: If you plan to extend the trip for any reason you **must** notify the Committee.*

Destination(s): Kampala & Entebbe, Uganda

Explain how this trip is specifically connected to the traveler's official or representational duties:

As Legislative Aide assigned to the health portfolio, this trip will be a resource to better understand how investments in NIH, CDC, USAID, and DoD advance R&D for new tools including drugs, vaccines, and diagnostics for long-standing global health challenges and emerging infectious diseases.

Name of accompanying family member (if any): _____

Relationship to Employee: ☐ Spouse ☐ Child

I certify that the information contained in this form is true, complete and correct to the best of my knowledge:

07/12/2019
(Date)

(Signature of Employee)

TO BE COMPLETED BY SUPERVISING SENATOR/OFFICER (President of the Senate, Secretary of the Senate, Sergeant at Arms, Secretary for the Majority, Secretary for the Minority, and Chaplain):

I, Sen. Lisa Murkowski *(Print Senator's/Officer's Name)* hereby authorize Angela Ramponi *(Print Traveler's Name)*

an employee under my direct supervision, to accept payment or reimbursement for necessary transportation, lodging, and related expenses for travel to the event described above. I have determined that this travel is in connection with his or her duties as a Senate employee or an officeholder, and will not create the appearance that he or she is using public office for private gain.

I have also determined that the attendance of the employee's spouse or child is appropriate to assist in the representation of the Senate. *(signify "yes" by checking box)* ☐

07/12/2019
(Date)

(Signature of Supervising Senator/Officer)

(Revised 10/19/15)

Form RE-1